Ironwood Pharmaceuticals INC 10-Q quarterly reports

Ironwood Pharmaceuticals reported a significant increase in net income for Q3 2025, driven by higher LINZESS sales and reduced operating expenses, despite a required confirmatory Phase III trial for apraglutide and ongoing restructuring.

Ironwood Pharmaceuticals reports a significant quarterly net income turnaround driven by cost reductions, despite a revenue decline and an FDA requirement for a confirmatory Phase III trial for apraglutide.

Ironwood Pharmaceuticals' Q1 2025 revenue decreased due to lower LINZESS sales, prompting a strategic review while the company advances its pipeline.

Ironwood Pharmaceuticals reported a net income of $3.6 million for the third quarter of 2024, a decrease compared to the $14 million net income in the same period last year, while also highlighting progress in its clinical pipeline.

Ironwood Pharmaceuticals reported a net loss for Q2 2024, impacted by decreased LINZESS revenue, while highlighting progress with its apraglutide program.

Ironwood Pharmaceuticals reported a net loss for the first quarter of 2024, primarily due to a decrease in LINZESS revenue, despite advancements in their apraglutide program.